Pivotal bioVenture Partners Investment Advisor LLC
CIK: 1844645
Holdings (13)
Q2 2026 13F, quarter ended Jun 30, 2026, filed Aug 13, 2026
- PCVX
VAXCYTE INC
$82.86M
1.43M sh26.92%+3.9% - ARQT
ARCUTIS BIOTHERAPEUTICS INC
$33.18M
1.27M sh10.78%-6.7% - TRVI
TREVI THERAPEUTICS INC
$32.5M
1.74M sh10.56%+12.2% - AVLN
AVALYN PHARMACEUTICALS INC
$31.83M
966,792 sh10.34%New - EVMN
EVOMMUNE INC
$25.61M
1.93M sh8.32%+0.0% - MPLT
MAPLIGHT THERAPEUTICS INC
$21.91M
611,446 sh7.12%+0.0% - OCS
OCULIS HOLDING AG
$20.89M
1.51M sh6.79%-10.4% - BIOA
BIOAGE LABS INC
$16.01M
653,374 sh5.20%+0.0% - IMNM
IMMUNOME INC
$15.52M
732,512 sh5.04%+0.0% - ZBIO
ZENAS BIOPHARMA INC
$12.46M
490,766 sh4.05%-17.1% - AVTX
AVALO THERAPEUTICS INC
$8.02M
434,033 sh2.61%+46.7% - RLYB
RALLYBIO CORP
$4.81M
300,579 sh1.56%+0.0% - RXRX
RECURSION PHARMACEUTICALS IN
$2.19M
595,518 sh0.71%+0.0%
| Security | Shares | Value | Change | Weight | Period |
|---|---|---|---|---|---|
 PCVX VAXCYTE INC | 1.43M | $82.86M | +3.9% | 26.92% | Q2 2026 |
 ARQT ARCUTIS BIOTHERAPEUTICS INC | 1.27M | $33.18M | -6.7% | 10.78% | Q2 2026 |
 TRVI TREVI THERAPEUTICS INC | 1.74M | $32.5M | +12.2% | 10.56% | Q2 2026 |
 AVLN AVALYN PHARMACEUTICALS INC | 966,792 | $31.83M | New | 10.34% | Q2 2026 |
 EVMN EVOMMUNE INC | 1.93M | $25.61M | +0.0% | 8.32% | Q2 2026 |
 MPLT MAPLIGHT THERAPEUTICS INC | 611,446 | $21.91M | +0.0% | 7.12% | Q2 2026 |
 OCS OCULIS HOLDING AG | 1.51M | $20.89M | -10.4% | 6.79% | Q2 2026 |
 BIOA BIOAGE LABS INC | 653,374 | $16.01M | +0.0% | 5.20% | Q2 2026 |
 IMNM IMMUNOME INC | 732,512 | $15.52M | +0.0% | 5.04% | Q2 2026 |
 ZBIO ZENAS BIOPHARMA INC | 490,766 | $12.46M | -17.1% | 4.05% | Q2 2026 |
 AVTX AVALO THERAPEUTICS INC | 434,033 | $8.02M | +46.7% | 2.61% | Q2 2026 |
 RLYB RALLYBIO CORP | 300,579 | $4.81M | +0.0% | 1.56% | Q2 2026 |
 RXRX RECURSION PHARMACEUTICALS IN | 595,518 | $2.19M | +0.0% | 0.71% | Q2 2026 |
1-13 of 13 holdings
Sector Allocation
SEC Filings
| Form | Description | Filed |
|---|---|---|
About Pivotal bioVenture Partners Investment Advisor LLC
Pivotal bioVenture Partners Investment Advisor LLC is an Investment Adviser that reports its US-listed stock and option positions to the SEC on Form 13F (CIK 1844645). Signal8 holds 20 13F filings from it. Its SEC filings list Delaware as its state of incorporation.
Its most recent 13F holdings report covers Q2 2026 (the quarter ended Jun 30, 2026) and was filed on Aug 13, 2026. That report lists 13 securities, not counting options, the same number as in Q1 2026.
Its five largest reported positions, in order, are VAXCYTE INC (PCVX), ARCUTIS BIOTHERAPEUTICS INC (ARQT), TREVI THERAPEUTICS INC (TRVI), AVALYN PHARMACEUTICALS INC (AVLN) and EVOMMUNE INC (EVMN). The next five are MAPLIGHT THERAPEUTICS INC (MPLT), OCULIS HOLDING AG (OCS), BIOAGE LABS INC (BIOA), IMMUNOME INC (IMNM) and ZENAS BIOPHARMA INC (ZBIO).
Recent 13F filings by Pivotal bioVenture Partners Investment Advisor LLC
- Q2 2026: 13F-HR filed Aug 13, 2026, listing 13 securities.
- Q1 2026: 13F-HR filed May 14, 2026, listing 13 securities.
- Q4 2025: 13F-HR filed Feb 13, 2026, listing 12 securities.
- Q3 2025: 13F-HR filed Nov 13, 2025, listing 10 securities.
- Q2 2025: 13F-HR filed Aug 13, 2025, listing 12 securities.
- Q1 2025: 13F-HR filed May 14, 2025, listing 11 securities.